menu
    • menu

    Company profile for Evolus

    NEW Drugs in Dev: 5
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Evolus’ primary market is self-pay healthcare. Our lead product is a proprietary 900 kDa purified botulinum toxin type A formulation.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EvolusUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    520 Newport Center Drive Suite 1200 Newport Beach, CA 92660
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.evolus.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/evolusexperience
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Evolus Reports Q1 2026 Results; Second Straight Positive EBITDA
    Evolus Reports Q1 2026 Results; Second Straight Positive EBITDA

    04 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260504795495/en/Evolus-Reports-First-Quarter-2026-Financial-Results-Company-Delivers-Second-Consecutive-Quarter-of-Positive-Adjusted-EBITDA-and-Reaffirms-Full-Year-Outlook

    BUSINESSWIRE
    04 May 2026
    Share Share
    Evolus to Participate in Needham Annual Healthcare Conference
    Evolus to Participate in Needham Annual Healthcare Conference

    31 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260331889362/en/Evolus-to-Participate-in-the-Needham-25th-Annual-Virtual-Healthcare-Conference

    BUSINESSWIRE
    31 Mar 2026
    Share Share
    Evolus To Join Leerink Partners Global Healthcare Conference
    Evolus To Join Leerink Partners Global Healthcare Conference

    25 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260225101738/en/Evolus-to-Participate-in-The-Leerink-Partners-Global-Healthcare-Conference

    BUSINESSWIRE
    25 Feb 2026
    Share Share
    Evolus To Release 2025 Financial Results On March 3, 2026
    Evolus To Release 2025 Financial Results On March 3, 2026

    17 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260217251838/en/Evolus-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-March-3-2026

    BUSINESSWIRE
    17 Feb 2026
    Share Share
    Evolus Issues Inducement Grants Per Nasdaq LR 5635(C)(4)
    Evolus Issues Inducement Grants Per Nasdaq LR 5635(C)(4)

    13 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260213973540/en/Evolus-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    13 Feb 2026
    Share Share
    Evolus Reveals 2025 Net Revenue Figures
    Evolus Reveals 2025 Net Revenue Figures

    09 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260109016727/en/Evolus-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2025-Net-Revenue

    BUSINESSWIRE
    09 Jan 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search